体内研究 (In Vivo) |
CP94253 (1-10 mg/kg;腹腔注射;单次给药) hydrochloride 可剂量依赖性地减少雌性 Wistar 大鼠的摄食量,其在首次摄食 1 小时内的腹腔注射 ED50 为 3.48 mg/kg;该药物的摄食抑制作用不依赖 5-HT2C 受体,且预先给予低剂量无活性的 5-HT2C 激动剂 ORG 37684 (MS-M04334) 可增强其摄食抑制效应。 CP94253 (5 mg/kg;腹腔注射;单次给药) hydrochloride 在小鼠中发挥强效类抗抑郁作用,可将强迫游泳实验中的不动时间缩短 43%;其作用机制为激活 5-HT1B 受体 (可能为突触后受体或异源受体),且多巴胺和去甲肾上腺素系统对该作用有介导作用。 CP94253 (0.5-10.0 mg/kg;皮下注射) hydrochloride 激活 5-HT1B 受体,可在雄性 Wistar 大鼠中呈剂量依赖性增加觉醒时长,在 5.0-10.0 mg/kg 剂量下减少慢波睡眠 (SWS),并在所有测试剂量下抑制快速眼动睡眠 (REMS)。 CP94253 (5.0-10.0 mg/kg;皮下注射) hydrochloride 诱导的雄性 Wistar 大鼠觉醒时间增加和慢波睡眠 (SWS) 减少可被 2.0 mg/kg (±) Pindolol (MS-M23863) 预处理逆转。 CP94253 (3.2-32 mg/kg;口服;每日一次;连续 9 天) hydrochloride 经口服给予健康大鼠后,在 32 mg/kg 剂量下会引发短暂厌食、持续的体重增长减缓以及持续性活动过度,而 3.2 mg/kg 和 10 mg/kg 剂量对这些终点指标无显著影响。 CP94253 (3-17 mg/kg;腹腔注射;单次给药) hydrochloride 可剂量依赖性地降低雄性 CFW 小鼠的种属特异性攻击行为,其中其减少攻击撕咬的 ED50 为 7.2 mg/kg;GR 127935 (MS-I73621) 的拮抗作用以及 WAY 100,635 (MS-L56483) 无作用的结果表明,该效应特异性作用于 5-HT1B 受体,且不会同时引发运动性镇静。 CP94253 (3-10 mg/kg;腹腔注射;单次给药) hydrochloride 可降低雄性 CFW 小鼠中酒精诱导增强的攻击性,其 ED50 (3.8 mg/kg) 低于针对非增强攻击性的 ED50;该药物具有剂量依赖性效应,仅在测试的最高剂量下会降低自主活动行为。 CP94253 (1-10 mg/kg;腹腔注射;单次给药) hydrochloride 可降低雄性 CFW 小鼠经激惹诱导的攻击性,其 ED50 (2.7 mg/kg) 低于非激惹诱导的攻击性模型;仅在较高剂量下,该药物才会对自发活动行为产生剂量依赖性影响。 CP94253 (5-40 µmol/kg;腹腔注射;喂食前 30 分钟单次给药) hydrochloride 可在轻度禁食的进食颗粒饲料大鼠中产生强效摄食抑制作用,其 ID50 为 12.5 µmol/kg;该作用通过缩短进食时长、降低进食频率实现,且不会改变大鼠的静息行为。 CP94253 (5-28 µmol/kg;腹腔注射;蔗糖摄入前 30 分钟单次给药) hydrochloride 可在轻度禁食且摄入 10% 蔗糖的大鼠中产生摄食抑制效应,其 ID50 为 22.8 µmol/kg;该效应通过缩短进食时长、降低进食频率及舔舐爆发/集群频率实现,且不会损害口腔运动效率。
| Animal Model: |
Wistar (female, ~200 g body weight) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Induced a dose-dependent reduction of food intake, with an ED50 value of 3.48 mg/kg for the first hour of food access. Showed hypophagic effect unaffected by pretreatment with 5-HT2C receptor antagonists metergoline or SB 242,084. Had hypophagic effect potentiated by pretreatment with a low, inactive dose of ORG 37684, lowering its ED50 to 2.44 mg/kg for the 0-1 h interval, 1.19 mg/kg for the 0-2 h interval, and 1.93 mg/kg for the 0-6 h interval. |
| Animal Model: |
Albino Swiss (male, 24-26 g) |
| Dosage: |
5 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Shortened the immobility time of mice by 43%. Did not alter spontaneous locomotor activity of mice. |
| Animal Model: |
Wistar (male, 350-380 g, implanted with chronic sleep recording electrodes, habituated to recording chambers and injection procedures) |
| Dosage: |
0.5 mg/kg; 1.0 mg/kg; 5.0 mg/kg; 10.0 mg/kg |
| Administration: |
s.c. |
| Result: |
Decreased REM sleep to 8.8 minutes and number of REM periods to 3.5 during 0-3 hour period at 0.5 mg/kg; no significant changes to waking, slow wave sleep, or light sleep observed at 0.5 mg/kg. Decreased REM sleep to 4.3 minutes and number of REM periods to 2.0, and increased REM sleep latency to 90.8 minutes during 0-3 hour period at 1.0 mg/kg; decreased REM sleep to 11.0 minutes and number of REM periods to 4.1 during 4-6 hour period at 1.0 mg/kg. Increased waking to 86.0 minutes, decreased slow wave sleep to 71.9 minutes and REM sleep to 1.4 minutes, increased REM sleep latency to 164.6 minutes, and decreased number of REM periods to 0.7 during 0-3 hour period at 5.0 mg/kg; increased waking to 58.4 minutes, decreased slow wave sleep to 92.6 minutes and REM sleep to 4.7 minutes, and decreased number of REM periods to 2.3 during 4-6 hour period at 5.0 mg/kg. Increased waking to 96.9 minutes and light sleep to 34.5 minutes, decreased slow wave sleep to 48.3 minutes and REM sleep to 0.3 minutes, increased slow wave sleep latency to 23.4 minutes and REM sleep latency to 239.2 minutes, and decreased number of REM periods to 0.2 during 0-3 hour period at 10.0 mg/kg; increased waking to 79.9 minutes and light sleep to 36.8 minutes, decreased slow wave sleep to 59.1 minutes and REM sleep to 4.2 minutes, and decreased number of REM periods to 2.0 during 4-6 hour period at 10.0 mg/kg. |
| Animal Model: |
Wistar (male, 350-380 g, implanted with chronic sleep recording electrodes, pretreated with (±) pindolol) |
| Dosage: |
5.0 mg/kg plus 2.0 mg/kg (±) Pindolol; 10.0 mg/kg plus 2.0 mg/kg (±) Pindolol |
| Administration: |
s.c. |
| Result: |
Decreased REM sleep to 2.9 minutes and number of REM periods to 1.6, and increased REM sleep latency to 125.0 minutes during 0-3 hour period at 5.0 mg/kg with (±) Pindolol pretreatment. Decreased REM sleep to 6.0 minutes and number of REM periods to 2.9 during 4-6 hour period at 5.0 mg/kg with (±) Pindolol pretreatment. No significant changes to waking or slow wave sleep observed at 5.0 mg/kg with (±) Pindolol pretreatment. Decreased REM sleep to 2.7 minutes and number of REM periods to 1.6, and increased REM sleep latency to 135.6 minutes during 0-3 hour period at 10.0 mg/kg with (±) Pindolol pretreatment. Decreased REM sleep to 3.4 minutes and number of REM periods to 3.1 during 4-6 hour period at 10.0 mg/kg with (±) Pindolol pretreatment. No significant changes to waking or slow wave sleep observed at 10.0 mg/kg with (±) Pindolol pretreatment. |
| Animal Model: |
Charles River Sprague-Dawley CD (male, 170-190 g) |
| Dosage: |
3.2 mg/kg; 10 mg/kg; 32 mg/kg |
| Administration: |
p.o.; daily; 9 days |
| Result: |
Reduced food intake significantly in the first 24 hours (to ~14 g/24 hr, compared to vehicle ~24 g/24 hr), with the anorectic effect diminishing over time and returning to vehicle levels by day 7. Inhibited body weight gain after the first and second injections, with a persistent weight differential relative to vehicle-treated rats maintained for the entire study (day 9 body weight ~290 g, compared to vehicle ~320 g). Induced a ~2-fold increase in horizontal locomotion relative to vehicle starting on day 1, which persisted throughout the 9-day study with slight evidence of tolerance. Showed no significant effect on food intake or body weight gain relative to vehicle at 3.2 mg/kg and 10 mg/kg. Exerted little or no effect on horizontal locomotion at 3.2 mg/kg and 10 mg/kg. |
| Animal Model: |
CFW (male, adult, 20-25 g, arrived at 5 weeks old) |
| Dosage: |
3.0 mg/kg; 5.6 mg/kg; 10.0 mg/kg; 17.0 mg/kg; 10 mg/kg plus GR 127935; 17 mg/kg plus GR 127935; 30 mg/kg plus GR 127935 |
| Administration: |
i.p.; single dose |
| Result: |
Reduced attack bite and tail rattle frequencies significantly at all tested doses (3-17 mg/kg). Reduced sideways threats significantly at 10.0 and 17.0 mg/kg. Achieved an ED50 of 7.2 mg/kg for attack bite reduction. Shifted the ED50 for attack bite reduction to 14.5 mg/kg when pretreated with GR 127935. Shifted the ED50 for sideways threat reduction to 15.6 mg/kg when pretreated with GR 127935. Did not alter anti-aggressive effects when pretreated with WAY 100,635. Did not reduce locomotor behaviors (walking, rearing) at any tested dose. Decreased grooming duration at all doses. |
| Animal Model: |
CFW (male, adult, 20-25 g, arrived at 5 weeks old) |
| Dosage: |
3.0 mg/kg; 5.6 mg/kg; 10.0 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Reduced attack bite and sideways threat frequencies significantly at all tested doses (3-10 mg/kg). Reduced tail rattle frequency at 10.0 mg/kg. Achieved an ED50 of 3.8 mg/kg for attack bite reduction in alcohol-heightened aggression mice, which was significantly lower than the ED50 of 7.1 mg/kg in alcohol-non-heightened aggression mice. Reduced locomotor behaviors (walking, rearing) only at the 10.0 mg/kg dose. Did not significantly affect grooming duration. |
| Animal Model: |
CFW (male, adult, 20-25 g, arrived at 5 weeks old) |
| Dosage: |
1.0 mg/kg; 3.0 mg/kg; 10.0 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Reduced attack bite and sideways threat frequencies significantly at 3.0 and 10.0 mg/kg. Achieved an ED50 of 2.7 mg/kg for attack bite reduction in instigation-heightened aggression mice, which was significantly lower than the ED50 of 8.3 mg/kg for non-instigated aggression. Reduced walking duration at 3.0 and 10.0 mg/kg. Reduced rearing and grooming durations only at 10.0 mg/kg. |
| Animal Model: |
Sprague-Dawley (male, mildly food-deprived) |
| Dosage: |
5 µmol/kg; 10 µmol/kg; 14 µmol/kg; 20 µmol/kg; 40 µmol/kg |
| Administration: |
i.p.; single injection 30 minutes prior to feeding |
| Result: |
Produced a dose-related decrease in 30-minute pellet intake, with significant reductions at 10, 14, 20, and 40 µmol/kg. Reduced water intake in a non-systematic, non-dose-related manner across all doses. Reduced the frequency of feeding observations at all doses. Shortened meal duration in a dose-related manner. Increased standing at the 20 µmol/kg dose. Left resting frequency unchanged. Induced an abnormal prone posture at the 40 µmol/kg dose. Achieved an ID50 of 12.5 µmol/kg for pellet intake reduction. |
| Animal Model: |
Sprague-Dawley (male, mildly food-deprived) |
| Dosage: |
5 µmol/kg; 10 µmol/kg; 14 µmol/kg; 20 µmol/kg; 40 µmol/kg |
| Administration: |
i.p.; single injection 30 minutes prior to sucrose access |
| Result: |
Produced a dose-related decrease in 30-minute sucrose intake, with significant reductions at 20 and 28 µmol/kg. Reduced the frequency of feeding observations at 20 and 28 µmol/kg. Shortened meal duration in a dose-related manner. Increased standing at the 28 µmol/kg dose. Left resting frequency unchanged. Reduced the total number of licks at 20 and 28 µmol/kg, with lick efficiency unchanged. Decreased the frequency of licking bursts and clusters without altering their size. Achieved an ID50 of 22.8 µmol/kg for sucrose intake reduction. |
|